Received Jun 26, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | KD27Z | — |
Twinrix - Late dosing schedule; This non-serious case was reported by a other health professional via call center representative and described the occurrence of drug dose administration interval too long in a 87-year-old female patient who received HAB (Twinrix) suspension for injection in pre-filled syringe (batch number KD27Z with expiry date 08-SEP-2028) for prophylaxis. Previously administered products included Twinrix (received first dose on 01-MAY-2025). On 13-APR-2026, the patient received the 2nd dose of Twinrix. On 13-APR-2026, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: Twinrix - Late dosing schedule). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 23-JUN-2026 The 87-year-old female patient received the first dose of Twinrix on 01-MAY-2025 and the second dose was administered on 13-APR-2026. The batch number was not provided upon follow- up with the reporter.